Darya Chudova Biography and Net Worth

CTO of Guardant Health

Darya Chudova is the Chief Technology Officer at Guardant Health, where she oversees the company’s technology strategy and development. During her time at the company, Chudova served as the senior vice president, where she led the technical development of Guardant’s screening product, Shield™, as well as the therapy selection portfolio (Guardant360 LDT and CDx). Prior to Guardant Health, Chudova developed tools for clinical diagnostics and interpretation of genomic expression data at Veracyte, Inc., and non-invasive prenatal testing at Illumina, Inc. Chodova holds a Doctor of Philosophy degree from the University of California, Irvine.

What is Darya Chudova's net worth?: The estimated net worth of Darya Chudova is at least $754.28 thousand as of December 15th, 2025. Chudova owns 7,012 shares of Guardant Health stock worth more than $754,281 as of January 12th. This net worth approximation does not reflect any other investments that Chudova may own. Learn More about Darya Chudova's net worth.
How do I contact Darya Chudova?: The corporate mailing address for Chudova and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Darya Chudova's contact information.
Has Darya Chudova been buying or selling shares of Guardant Health?: Darya Chudova has not been actively trading shares of Guardant Health during the last quarter. Most recently, Darya Chudova sold 5,451 shares of the business's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $104.04, for a transaction totalling $567,122.04. Following the completion of the sale, the chief technology officer now directly owns 7,012 shares of the company's stock, valued at $729,528.48. Learn More on Darya Chudova's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Michael Bell (CFO), Derek Bertocci (CFO), Darya Chudova (CTO), Ian Clark (Director), Helmy Eltoukhy (CEO), Chris Freeman (Chief Commercial Officer, Oncology), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Terilyn Monroe (Insider), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, insiders at the sold shares 42 times. They sold a total of 1,082,007 shares worth more than $80,709,932.39. The most recent insider tranaction occured on January, 7th when insider Terilyn J Monroe sold 10,031 shares worth more than $1,124,274.48. Insiders at Guardant Health own 6.1% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 1/7/2026.

Darya Chudova Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2025	Sell	5,451	$104.04	$567,122.04	7,012
12/8/2025	Sell	9,271	$106.00	$982,726.00	12,463
12/8/2025	Sell	13,664	$105.04	$1,435,266.56	54,480

Darya Chudova Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $107.57

$103.80

$113.91

50 Day Range

MA: $102.14

$94.13

$112.33

2 Week Range

Now: $107.57

$34.88

$113.91

Volume

2,356,343 shs

Average Volume

2,524,306 shs

Market Capitalization

$13.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58